Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 and mFOLFIRI in Advanced RAS Positive Metastatic Colorectal Cancer
NCT02613650Phase 1Completed
- Sponsor
- University of Utah
- Start
- Aug 2016
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib in colorectal cancer (CRC), sponsored by University of Utah. Primary endpoint: Dose Limiting Toxicities. Started Aug 2016; status: completed.
02
Drugs
binimetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02613650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613650.